<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779896</url>
  </required_header>
  <id_info>
    <org_study_id>McG 0722</org_study_id>
    <nct_id>NCT00779896</nct_id>
  </id_info>
  <brief_title>Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study</brief_title>
  <official_title>Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1%
      cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled
      into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for
      up to 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial response (PR) is defined as some improvement (25%-50%);significant evidence of disease remains or disease has not changed from baseline condition (&lt;25%);no new clinically abnormal(&gt;1.5 cm)lymph nodes,&lt;25% progression of existence</measure>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Cutaneous T-Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazarotene</intervention_name>
    <description>Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase to once-daily application, if tolerated.</description>
    <other_name>Tazorac (trademark name)</other_name>
    <other_name>Tazarotenic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Stage I-IIA CTCL must be at least 18 years of age with a skin biopsy
             prior to enrolment confirming the diagnosis of mycosis fungoides.

        Exclusion Criteria:

          -  Patients with Stage &gt;IIA CTCL at the time of enrolment

          -  Women who are pregnant or planning to get pregnant, or unable/unwilling to use
             adequate contraception

          -  Patients who were treated with topical retinoid therapy in the past 3 months

          -  Patients who received any systemic CTCL therapy or systemic corticosteroid therapy
             within 30 days of the study start date

          -  Patients who were treated with systemic isotretinoin or bexarotene within 3 months
             prior to the study start date, systemic acitretin within 2 years prior to study start
             date
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Roberge</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Roberge</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>48080</phone_ext>
    <email>david.roberge@muhc.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Chipman</last_name>
      <phone>514-398-1444</phone>
      <email>penny.chipman@mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Crystal Lameira</last_name>
      <phone>514-398-2229</phone>
      <email>crystal.lameira@mcgill.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>October 22, 2008</last_update_submitted>
  <last_update_submitted_qc>October 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. David Roberger</name_title>
    <organization>McGill University</organization>
  </responsible_party>
  <keyword>To evaluate therapeutic potential of tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study</keyword>
  <keyword>Stage I-IIA disease CTCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazarotene</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

